Pan Cancer T raises €10M to advance its T cell therapies. The funding, led by existing investors, will support clinical trials for triple-negative breast cancer.
Amount Raised
€10 Million
Round Type
Funding Round
RotterdamBiotechnologyHealth CareInvestors
Description
Pan Cancer T, a Rotterdam-based biotech company, raised €10M in funding to further develop its T cell therapies. The round included €5M from existing investors and a €5M Innovation Credit loan. The funds will be used to advance their lead program into a clinical trial for triple-negative breast cancer. Founded in 2020, the company has raised approximately €21M to date.
Quick answer
Pan Cancer T raised €10 Million in a Funding Round round, dated December 8, 2025. Investors: InnovationQuarter, Erasmus Mc O&O Holdings, Thuja Capital and Van Herk Ventures. Pan Cancer T is based in Rotterdam, South Holland, Netherlands.
- How much did Pan Cancer T raise?
- Pan Cancer T raised €10 Million in a Funding Round round on December 8, 2025.
- Who invested in Pan Cancer T?
- InnovationQuarter, Erasmus Mc O&O Holdings, Thuja Capital and Van Herk Ventures are named as investors in this round.
- What does Pan Cancer T do?
- Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies.
- Where is Pan Cancer T based and how big is it?
- Pan Cancer T is based in Rotterdam, South Holland, Netherlands. Fundz records about 8 employees.
- Who are the decision-makers at Pan Cancer T?
- Fundz holds 2 contacts at Pan Cancer T, including the Founder. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Pan Cancer T that raised within 45 days of this round, from Fundz verified event records.
- Corxel Pharmaceuticals raised $287M (Series D) on January 22, 2026.
- Mendra raised $82M (Series A) on January 22, 2026.
- Cancilico raised $2.9M (Seed) on January 22, 2026.
- ErVimmune raised $20M (Series A) on January 21, 2026.
- Infinitopes raised $15M (Seed) on January 21, 2026.
- ImmunoMet Therapeutics raised $842K on January 21, 2026.
Who to call at Pan Cancer T, and when
A new round usually means Pan Cancer T is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Pan Cancer T raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pan Cancer T, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pan Cancer T. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pan Cancer T raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Pan Cancer T raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.